Literature DB >> 4105418

Immunity to Escherichia coli in pigs. The role of milk in protective immunity to e. coli enteritis.

M R Wilson, J Svendsen.   

Abstract

Milk whey from immunized sows increased the survival time of gnotobiotic piglets infected with Escherichia coli. The survival time of infected piglets fed milk whey from non-vaccinated sow's was the same as that of similar pigs fed condensed cow milk. The significance of milk antibodies in immune protection against E. coli enteritis is discussed and compared with that of absorbed colostral antibodies. From calculations presented it would appear that seven day old piglets receive approximately 1 g of gamma globulin daily from milk and that this is equal to the piglets total serum gamma globulin content. After seven days of age the gamma globulin content of piglet serum falls, whereas that of milk remains constant; milk is, therefore, potentially a major source of immunoglobulins with protective activity against E. coli associated enteritides.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4105418      PMCID: PMC1319614     

Source DB:  PubMed          Journal:  Can J Comp Med        ISSN: 0008-4050


  6 in total

1.  The effect of diet on the maturation of the neonatal piglet's serum protein profile and resistance to disease.

Authors:  J G LECCE; G MATRONE; D O MORGAN
Journal:  Ann N Y Acad Sci       Date:  1961-08-31       Impact factor: 5.691

2.  Transmissible gastro-enteritis of swine (TGE).

Authors:  S F Cartwright
Journal:  Br Vet J       Date:  1969-08

3.  Gnotobiotic pigs: procurement, microbial flora, serum proteins and lymphatic tissues.

Authors:  T J Alexander; O P Miniats; D G Ingram; R G Thomson; E L Thackeray
Journal:  Can Vet J       Date:  1969-04       Impact factor: 1.008

4.  Experimental immunisation of sows against transmissible gastroenteritis. I. Immunisation with a bacteria-free suspension of transmissible gastroenteritis virus prepared from the intestines of infected pigs.

Authors:  S Djurickovic; J Thorsen
Journal:  Vet Rec       Date:  1970-07-18       Impact factor: 2.695

5.  Studies of Escherichia coli in gnotobiotic pigs 3. Evaluation of orally administered specific antisera.

Authors:  E M Kohler; E H Bohl
Journal:  Can J Comp Med Vet Sci       Date:  1966-08

6.  Studies of escherichia coli in gnotobiotic pigs. IV. Comparison of enteropathogenic and nonenteropathogenic strains.

Authors:  E M Kohler
Journal:  Can J Comp Med Vet Sci       Date:  1967-11
  6 in total
  7 in total

1.  Immunoglobulin-containing cells in pig mammary gland.

Authors:  P J Brown; F J Bourne; H R Denny
Journal:  J Anat       Date:  1975-11       Impact factor: 2.610

2.  Comparison of the direct agglutination and indirect hemagglutination tests in the determination of blood serum titers to Escherichia coli organisms.

Authors:  I A Schipper; C Kelling; H Ebeltoft; D Graves
Journal:  Appl Microbiol       Date:  1973-03

3.  Intestinal antibody secretion in the young pig in response to oral immunization with Escherichia coli.

Authors:  P Porter; R Kenworthy; D E Noakes; W D Allen
Journal:  Immunology       Date:  1974-11       Impact factor: 7.397

4.  Immunity to Escherichia coli in pigs: antibody secretion by the mammary gland after intramammary or intramuscular vaccination with an E. coli vaccine.

Authors:  M R Wilson; P Brown; J Svendsen
Journal:  Can J Comp Med       Date:  1972-01

5.  Immunity to Escherichia coli in pigs: serum gamma globulin levels, indirect hemagglutinating antibody titres and bactericidal activity against E. coli in pigs up to five weeks of age.

Authors:  M R Wilson; J Svendsen
Journal:  Can J Comp Med       Date:  1972-01

6.  Escherichia coli-associated porcine neonatal diarrhea: antibacterial activities of colostrum from genetically susceptible and resistant sows.

Authors:  R Sellwood
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

7.  Phenotyping of E. coli serotypes associated to oedema disease.

Authors:  Sigbrit Mattsson; Per Wallgren
Journal:  Acta Vet Scand       Date:  2008-06-02       Impact factor: 1.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.